Table 3.
Treatments and outcomes in anti-LGI1 encephalitis.
| Total | Complete remission | Remission | Relapsed | |
|---|---|---|---|---|
| n/N (%)a | n/N (%)b | n/N (%)b | n/N (%)b | |
| Steroids only | 97/241 (40.25%) | 22/43 (51.16%) | 18/43 (41.86%) | 9/43 (20.93%) |
| IVIG only | 38/241 (15.77%) | 9/16 (56.25%) | 5/16 (31.25%) | 1/16 (6.25%) |
| Steroids and IVIG | 100/241 (41.49%) | 25/60 (41.67%) | 33/60 (55.00%) | 5/60 (8.33%) |
| PE* | 20/319 (6.27%) | 4/12 (33.33%) | 6/12 (50.00%) | 5/12 (41.67%) |
| Immunosuppressants* | 47/358 (13.13%) | 5/13 (38.46%) | 8/13 (61.54%) | 5/13 (38.46%) |
| Total | 358/390 (91.79%) | 142/295 (48.14%) | 111/295 (37.63%) | 35/295 (11.86%) |
IVIG, intravenous immunoglobulin; PE, Plasma exchange.
Data reported as n/N (%), where N is the total number of patients with details of each therapy and n is the number of patients who received the mentioned therapy.
Data reported as n/N (%), where N is the total number of patients analyzed in the initial visit of each therapy and n is the number of patients in different outcomes who received each therapy in the initial visit.
PE*, PE was not used alone according to our results. The combined therapy included PE with steroids, PE with steroids and IVIG, PE with steroids and immunosuppressants, and PE with steroids, IVIG, and immunosuppressants. Immunosuppressants*: Immunosuppressants were not used alone according to our results. The combined therapy included immunosuppressants with steroids, immunosuppressants with steroids and IVIG, immunosuppressants with steroids and PE, and immunosuppressants with steroids, IVIG, and PE.